Sign up to save your podcasts
Or
Share Using Real World Data to Individualize HCV Management
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Using Real World Data to Individualize HCV Management
Volume 5, Issue 8.
In this podcast, Andrew J. Muir, MD from Duke University School of Medicine discusses the real-world data to support a sofosbuvir-ledipasvir treatment duration of 8 weeks versus 12 weeks, summarizes the current hepatitis C treatment options for patients with advanced kidney disease, and describes the risks and benefits of hepatitis C therapies in HIV-HCV coinfected patients.
Take our post-test to claim CME credits:
Physician post-test
Nurse post-test
To read a companion newsletter click here.
The post Using Real World Data to Individualize HCV Management appeared first on DKBmed Radio.
Hosted on Acast. See acast.com/privacy for more information.
View all episodes
By eViralHepatitis Review
5
11 ratings
Volume 5, Issue 8.
In this podcast, Andrew J. Muir, MD from Duke University School of Medicine discusses the real-world data to support a sofosbuvir-ledipasvir treatment duration of 8 weeks versus 12 weeks, summarizes the current hepatitis C treatment options for patients with advanced kidney disease, and describes the risks and benefits of hepatitis C therapies in HIV-HCV coinfected patients.
Take our post-test to claim CME credits:
Physician post-test
Nurse post-test
To read a companion newsletter click here.
The post Using Real World Data to Individualize HCV Management appeared first on DKBmed Radio.
Hosted on Acast. See acast.com/privacy for more information.